相关临床试验
2197
1847 进行中
药物批准
58
批准总数
监管机构
2
监管机构数
成立时间
N/A
终止
1
0.1%
招募中
304
13.8%
暂停
5
0.2%
进行中（未招募）
1837
83.6%
已完成
40
1.8%
尚未招募
10
0.5%
- SciNeuro Pharmaceuticals has entered a worldwide licensing agreement with Novartis for $165 million upfront and up to $1.5 billion in potential milestones to develop next-generation Alzheimer's therapeutics. - The partnership centers on SciNeuro's novel amyloid-beta targeted antibody program that incorporates proprietary blood-brain barrier shuttle technology designed to improve drug delivery to the brain. - Novartis will receive exclusive worldwide rights to develop and commercialize the program, with both companies collaborating during early development before Novartis takes full responsibility for clinical trials and commercialization. - The transaction addresses a major challenge in neurodegenerative drug development by potentially overcoming limited brain tissue penetration that has hindered previous Alzheimer's treatments.
- Transition Bio and Voyager Therapeutics have entered a drug discovery collaboration to develop novel small molecules targeting TDP-43 pathology in ALS and frontotemporal dementia. - The partnership leverages Transition Bio's biomolecular condensate technology to address TDP-43, which affects over 90% of ALS cases and up to 45% of FTD cases. - Under the agreement, Transition Bio received a single-digit million-dollar upfront payment and is eligible for up to $500 million in milestone payments plus royalties. - The collaboration aims to correct TDP-43 mislocalization while preserving the protein's essential cellular functions, addressing a historically challenging therapeutic target.
